Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
Open Access
- 5 November 2015
- journal article
- review article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (2) , 358-370
Abstract
Ulcerative colitis (UC) is a chronic idiopathic inflammatory disorder in which patients cycle between active disease and remission. Budesonide multi-matrix (MMX) is an oral second-generation corticosteroid designed to deliver active drug throughout the colon. In pharmacokinetic studies, the mean relative absorption of budesonide in the region between the ascending colon and the descending/sigmoid colon was 95.9 %. In 2 identically designed, phase 3 studies (CORE I and II), budesonide MMX 9 mg once daily was efficacious and well tolerated for induction of remission of mild to moderate UC. Clinical and endoscopic remission rates were 17.9 % (CORE I) and 17.4 % (CORE II) for budesonide MMX 9 mg compared with 7.4 and 4.5 %, respectively, with placebo (p < 0.05, budesonide MMX 9 mg vs. placebo in both studies), 12.1 % with mesalamine 2.4 g, and 12.6 % with budesonide controlled ileal release capsules 9 mg. A 12-month maintenance therapy study suggested that budesonide MMX 6 mg may prolong time to clinical relapse: Median time was >1 year with budesonide MMX 6 mg versus 181 days (p = 0.02) with placebo; however, further studies are needed. In the CORE studies, budesonide MMX exhibited a favorable safety profile; the majority of adverse events were mild or moderate in intensity, and serious adverse events were uncommon. Furthermore, rates of potential glucocorticoid-related adverse events were comparable across treatment groups. The long-term (12-month) safety of budesonide MMX appears to be comparable with placebo. Data support budesonide MMX in the management algorithm of UC.Keywords
This publication has 58 references indexed in Scilit:
- Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II studyGut, 2013
- Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitisBMC Gastroenterology, 2012
- Direct Health Care Insurer and Out-of-Pocket Expenditures of Inflammatory Bowel Disease: Evidence from a US National SurveyDigestive Diseases and Sciences, 2012
- Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and AdultsGastroenterology, 2008
- Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitisGut, 2008
- Budesonide as maintenance treatment in Crohn's disease: a placebo‐controlled trialAlimentary Pharmacology & Therapeutics, 2005
- A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitisClinical Gastroenterology and Hepatology, 2003
- Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's diseaseGut, 2001
- Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s diseaseGut, 1998
- Oral budesonide as maintenance therapy in Crohn’s disease—results of a 12‐month studyAlimentary Pharmacology & Therapeutics, 1998